The contribution of school closures to youth mental health.
Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post Menopausal Osteoporosis.